© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#IDWeek 2019
Click Here for More Conferences
IDWeek 2019
Click Here for IDWeek Online
HIV: The Basics

Switching to Descovy for PrEP Improves Kidney and Bone Biomarkers

However, serious kidney problems and bone fractures were rare among people taking either Descovy or Truvada for HIV prevention.

Integrase Inhibitors May Raise Diabetes Risk in People With HIV

However, a recent study found that this varied based on the specific integrase inhibitor used.

Triple-Target Hepatitis B Vaccine May Be More Effective

Sci-B-Vac may offer more protection for older people and those with a weaker immune system.

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Grindr Users Have More Risky Sex but Are More Likely to Use PrEP

Users of the social media app had a higher rate of some sexually transmitted infections but a lower rate of HIV.

Providing Naloxone to People Who Inject Drugs During Hep C Care Drives Up Use

The drug can quickly reverse opioid-driven overdoses.

Oral Cabotegravir Combo Keeps HIV Suppressed for 6 Years

As long-acting injectables near approval, daily pill versions of the same drugs show long-term benefit.

Evidence Suggests HIV Treatment Adherence Declines Over Time

An analysis of 15,000 insured people with HIV also confirmed past findings that single-tablet regimens are associated with higher adherence.

Experimental Hepatitis C Vaccine Does Not Prevent Chronic Infection

People who received the vaccine did, however, show stronger immune responses against the virus.

Some People With HIV Still Experience Treatment Challenges

Surveys reveal difficulties associated with daily pills and a desire for long-acting injectable therapy.

Who Gains Weight After Switching to Integrase Inhibitors?

Researchers at George Washington University take a look.
Antibodies

Trogarzo Again Shown Effective Against Highly Resistant HIV

Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.
The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Advertisement
Science News
Opinions

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.